

Alberta Drug Benefit List (ADBL) interim update now available online

Please be advised that the **March 1, 2024** updates to the ADBL have been posted online at ab.bluecross.ca/dbl/publications.php.

Please refer to the **March 1, 2024** updates for complete listings of products available by special authorization, changes to criteria for coverage, restricted benefits, changes to benefit status, added products, new established interchangeable groupings, least cost alternative price changes and products with a price change.

Please note that the online *interactive Drug Benefit List (iDBL)* at ab.bluecross.ca/dbl/idbl_main1.php is a near real-time application, and as such, contains the most up-to-date information.

Temporary benefit added to the ADBL

Due to the unavailability for Xolair 150 mg Vial Injection (DIN 02260565) manufactured by Novartis Pharmaceuticals Canada Inc., **Xolair 150 mg Syringe Injection (DIN 02459795)** will be considered a temporary benefit for the ADBL. This grouping was added to the Critical Supply Product List February 6, 2024.

As of February 6, 2024, all claims for **Xolair 150 mg Syringe Injection (DIN 02459795)** will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The ABCDPL is available online at ab.bluecross.ca/provider/type/pharmacy/home.php.

Removal of temporary benefits from the ADBL

Due to the unavailability of the following amoxicillin oral suspensions, **Auro-Amoxicillin 25 mg/ml Oral Suspension (DIN 02458586)**, **Auro-Amoxicillin 50 mg/ml Oral Suspension (DIN 02458594)**, **Ceftin 125 mg/5 ml Oral Suspension (DIN 02212307)** manufactured by Sandoz Canada Inc., and Europe labelled **Moxilen Forte 50 mg/ml Oral Suspension (PIN 09858237)** manufactured by Medochemie Ltd. were added as temporary benefits for the ADBL.

DIN	Product description
00000628131	Apo-Amoxi 25 mg/ml Oral Suspension
00000628158	Apo-Amoxi 50 mg/ml Oral Suspension
00002352753	Amoxicillin 50 mg/ml Oral Suspension
00002401541	Amoxicillin 50 mg/ml Oral Suspension
00002352788	Amoxicillin Sugar-Reduced 50 mg/ml Oral Suspension
00002535815	Jamp-Amoxicillin 50 mg/ml Oral Suspension
00000452130	Novamoxin 50 mg/ml Oral Suspension
00001934163	Novamoxin Sugar-Reduced 50 mg/ml Oral Suspension

Alberta Blue Cross has confirmed that the shortages for amoxicillin oral suspensions have been resolved.

Auro-Amoxicillin 25 mg/ml Oral Suspension (DIN 02458586), **Auro-Amoxicillin 50 mg/ml Oral Suspension (DIN 02458594)**, **Ceftin 125 mg/5 ml Oral Suspension (DIN 02212307)**, and Europe labelled **Moxilen Forte 50 mg/ml Oral Suspension (PIN 09858237)** will no longer be considered temporary benefits for the ADBL **after March 19, 2024**. The above grouping was removed from the Critical Supply Product List February 20, 2024.

continued next page

PHARMACY BENEFACT

continued from previous page

Product supply shortages addressed for ADBL

Alberta Blue Cross has confirmed that the shortage for Odan-Amantadine 10 mg/ml Syrup (DIN 02538601) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 13, 2024**. The following grouping was removed from the Critical Supply Product List February 12, 2024.

AMANTADINE HCL

10 MG / ML ORAL SYRUP

00002538601	ODAN-AMANTADINE	ODN	\$ 0.0988
00002022826	PDP-AMANTADINE	PPH	\$ 0.1430

Alberta Blue Cross has confirmed that the shortage for Taro-Clindamycin/Benzoyl Peroxide 1%/5% Topical Gel (DIN 02440180) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 18, 2024**. The following grouping was removed from the Critical Supply Product List February 15, 2024.

CLINDAMYCIN PHOSPHATE/ BENZOYL PEROXIDE

1% / 5% TOPICAL GEL

00002440180	TARO-CLINDAMYCIN/BENZOYL PEROXIDE	TAR	\$ 0.6857
00002243158	CLINDOXYL	GSK	\$ 0.7500

Alberta Blue Cross has confirmed that the shortage for Ran-Ramipril HCTZ 5 mg/12.5 mg Tablet (DIN 02449447) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **March 18, 2024**. The following grouping was removed from the Critical Supply Product List February 16, 2024.

RAMIPRIL / HYDROCHLOROTHIAZIDE

5 MG / 12.5 MG TABLET

00002449447	RAN-RAMIPRIL HCTZ	RAN	\$ 0.3016
00002283158	ALTACE HCT	VCL	\$ 0.4221

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at

780-498-8370 (Edmonton and area)

403-294-4041 (Calgary and area)

1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area)

FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims.

Visit ab.bluecross.ca/providers/pharmacy-home.php

